[CAS NO. 31083-55-3] PRT4165
PRODUCTS SPECIFICATIONS [31083-55-3]
DESCRIPTION [31083-55-3]
Overview
| MDL | MFCD00435709 |
|---|---|
| Molecular Weight | 235.24 |
| Molecular Formula | C15H9NO2 |
| SMILES | O=C1/C(C(C2=C1C=CC=C2)=O)=C/C3=CC=CN=C3 |
4 Publications Citing Use of MCE
Summary
PRT4165 is a potent inhibitor of PRC1-mediated H2A ubiquitylation .
IC50 & Target
PRC1 [1]
In Vitro
PRT4165 is a potent inhibitor of PRC1-mediated H2A ubiquitylation. In vitro E3 ubiquitin ligase activity assays reveal that PRT4165 inhibits both RNF2 and RING 1A, but not RNF8 nor RNF168. In the presence of PRT4165, H2A ubiquitylation can be completely inhibited regardless of whether RING1 or RNF2 contributes the E3 ubiquitin ligase activity. Treatment of cells for 60 min with 50 μM PRT4165 results in a dramatic reduction in total ubiquitylated histone H2A. It is also found that longer exposure of the cells with the PRT4165 (30 and 60 min) leads to increased levels of γ-H2AX in unirradiated cells. PRT4165 inhibits double-strand break (DSB) repair at the 8-h time point compare with mock treated cells. Cells treated with increasing concentrations of PRT4165 show increasing numbers of cells in G 2 /M [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 25 mg/mL ( 106.27 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.2510 mL | 21.2549 mL | 42.5098 mL |
| 5 mM | 0.8502 mL | 4.2510 mL | 8.5020 mL |
| 10 mM | 0.4251 mL | 2.1255 mL | 4.2510 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (10.63 mM); Suspended solution; Need ultrasonic
Synonyms